Indication |
For use as adjunctive therapy to diet for the reduction of
elevated total-C, LDL-C, and Apo B in patients with primary
(heterozygous familial and non-familial) hypercholesterolemia. |
Pharmacodynamics |
Ezetimibe is in a class of lipid-lowering compounds that
selectively inhibits the intestinal absorption of cholesterol and
related phytosterols. Ezetimibe, administered alone is indicated as
adjunctive therapy to diet for the reduction of elevated total-C, LDL-C,
and Apo B in patients with primary (heterozygous familial and
non-familial) hypercholesterolemia. It is also used in combination
therapy with HMG-CoA reductase inhibitors. Ezetimibe has a mechanism of
action that differs from those of other classes of cholesterol-reducing
compounds (HMG-CoA reductase inhibitors, bile acid sequestrants, fibric
acid derivatives, and plant stanols). Ezetimibe does not inhibit
cholesterol synthesis in the liver, or increase bile acid excretion but
instead localizes and appears to act at the brush border of the small
intestine and inhibits the absorption of cholesterol, leading to a
decrease in the delivery of intestinal cholesterol to the liver. This
causes a reduction of hepatic cholesterol stores and an increase in
clearance of cholesterol from the blood; this distinct mechanism is
complementary to that of HMG-CoA reductase inhibitors. |
Mechanism of action |
Ezetimibe localizes and appears to act at the brush border of the
small intestine and inhibits the absorption of cholesterol, leading to a
decrease in the delivery of intestinal cholesterol to the liver. |
Absorption |
Not Available |
Volume of distribution |
Not Available |
Protein binding |
>90% |
Metabolism |
Hepatic, intestinal wall |
Route of elimination |
Ezetimibe is primarily metabolized in the small intestine and
liver via glucuronide conjugation (a phase II reaction) with subsequent
biliary and renal excretion. In humans, ezetimibe is rapidly metabolized
to ezetimibe-glucuronide. |
Half life |
22 hours |
Clearance |
Not Available |
Toxicity |
Not Available |